Bio-Techne (NASDAQ:TECH) is a U.S. company that supplies laboratory tools and services to research communities. It is currently the focus of a major acquisition offer from the German science and technology firm, Merck KGaA. This development creates significant activity around the company's stock and its valuation in the market.
On June 25, 2026, analyst firm William Blair issues a downgrade for Bio-Techne, changing its rating from "Outperform" to "Market Perform." A "Market Perform" rating suggests an analyst believes the stock will offer returns similar to the overall market, rather than exceeding it, which is what an "Outperform" rating implies.
The downgrade occurs as Merck KGaA announces a cash acquisition offer of $73 per share for Bio-Techne. This offer values the company at approximately $11.3 billion. In reaction to the news, Bio-Techne's stock price surges over 20%, closing at $70.67, very close to the price noted when the new rating was published.
William Blair's rating change to "Market Perform" likely reflects the acquisition offer. With the stock trading near the $73 offer price, there is limited potential for further significant gains. The analyst's rating suggests the stock's value is now tied to the successful completion of the proposed deal with Merck KGaA.
This offer comes just a week after activist investor Ananym Capital Management acquired a stake and pushed for a sale. Meanwhile, as highlighted by PR Newswire, the law firm Ademi LLP is investigating the transaction to determine if the board is securing a fair price for its public shareholders.
